Trials / Completed
CompletedNCT02078427
ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
ADVATE/ ADYNOVI Hemophilia A Outcome Database
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 951 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to document the natural history of hemophilia A disease and long-term outcomes in terms of effectiveness, safety and quality of life in participants receiving Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM) or Antihemophilic Factor (Recombinant) - Pegylated (rAHF-PEG) in routine clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ADVATE | Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method |
| BIOLOGICAL | ADYNOVI | Antihemophilic Factor (Recombinant) Pegylated |
Timeline
- Start date
- 2011-06-28
- Primary completion
- 2024-01-16
- Completion
- 2024-01-16
- First posted
- 2014-03-05
- Last updated
- 2024-06-17
Locations
110 sites across 22 countries: Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, Denmark, France, Greece, Hungary, Italy, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02078427. Inclusion in this directory is not an endorsement.